This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investing in Karolinska Development AB (publ) ...
Karolinska Development (STO:KDEV) has slashed the value of its portfolio after adopting a new way of tallying up what its early-stage biotech investments are worth. The new accounting model and the ...
Karolinska Development (STO:KDEV) has stopped investing in three of its portfolio biotechs and fully written off its outlay in the businesses to date. The decisions contributed to the valuation of the ...
STOCKHOLM, SWEDEN – August 20, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its Chairman of the Board, Professor Hans Wigzell, has informed the Board that he resigns ...
STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with a ...
STOCKHOLM, SWEDEN - July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon ...
STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part 1 ...
STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company’s IND application ...
If the original Linux-based FoxBox SMS didn't boast quite the capabilities you were looking for, then perhaps KDev's upgraded FoxBox MMS will be more to your liking. Like the original FoxBox, it'll ...
New firm will include existing portfolio company Akinion and four to five new project businesses. Swedish life science investor and incubator organization Karolinska Development has established a new ...
(MENAFN- GlobeNewsWire - Nasdaq) STOCKHOLM, SWEDEN – October 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has been granted a patent in ...
Karolinska Development AB ( (SE:KDEV)) has issued an update. Karolinska Development’s portfolio company, Modus Therapeutics, has initiated dosing in the second part of a phase 2a clinical study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results